Article

Cole National accepts Luxottica's final offer

Cleveland-Shareholders of Cole National Corp., the parent company of Pearl Vision, Sears Optical eyewear shops, and Things Remembered gift stores, have approved an amended deal to merge with Italian eyewear manufacturer Luxottica Group SpA.

Cleveland-Shareholders of Cole National Corp., the parent company of Pearl Vision, Sears Optical eyewear shops, and Things Remembered gift stores, have approved an amended deal to merge with Italian eyewear manufacturer Luxottica Group SpA.

The new $495 million deal increases Cole National's per-share price from $22.50 to $27.50 following a tumultuous process that saw several simultaneous bidders driving the price up from the original $19.65 price Luxottica offered in July 2003. Moulin International Holdings Ltd. of Hong Kong, the largest eyewear manufacturer in Asia, had jumped into the game in April 2004, just days before a stockholder meeting to consider the Luxottica offer. However, Moulin ran into trouble securing financing, giving Luxottica time to increase its offer.

The deal gives Luxottica some 2,200 additional outlets around the country. Cole Vision last posted a profit in fiscal 2000, and last year reported a $10.7 million loss.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.